Results 101 to 110 of about 11,332,305 (264)
Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery
Advanced Science, EarlyView.An injectable and tunable peptide‐based functional amyloid hydrogel provides sustained insulin release while preserving insulin stability and bioactivity. The hydrogel enables prolonged glycemic regulation in vivo, exhibits excellent biocompatibility, and shows no detectable IAPP and α‐Syn heterologous cross‐seeding, highlighting its potential as a ...
Ranjit Shaw +4 more
wiley +1 more source
AGING MEDICINE, EarlyView.Blood‐based biomarkers are emerging as accessible tools for Alzheimer's disease screening, diagnosis, risk stratification, and longitudinal monitoring. This review summarizes major biomarkers, including Aβ42/Aβ40, phosphorylated tau species, NfL, GFAP, genetic risk markers, and exploratory inflammatory, synaptic, and proteomic candidates.
Shuangshuang Li, Lin Huang, Qihao Guo
wiley +1 more source
Extending the ATP9A‐Related Phenotypic Spectrum: Indication of Schizophrenia Susceptibility
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, EarlyView.ABSTRACT ATP9A, which belongs to the P4‐ATPase family of proteins, is involved in the efficient transport of vesicles from the Golgi apparatus to the plasma membrane, as well as the release of extracellular vesicles from human cells. In 2021, a loss‐of‐function variant of this gene was identified as being associated with a recessive neurodevelopmental ...
Camille Verebi +10 more
wiley +1 more source
White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringWhite matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and ...
Antoine Garnier‐Crussard +7 more
doaj +1 more source
Journal of Education, Health and SportAlzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń +9 more
doaj +1 more source
Zooming in on Cerebral Amyloid Angiopathy in the Context of Amyloid-Related Imaging Abnormalities [PDF]
Innov AgingAbstract The significance of cerebral amyloid angiopathy (CAA) has been heightened since anti-amyloid therapies were approved. Amyloid-related imaging abnormalities (ARIA) are a major side effect of anti-amyloid therapies, and CAA is the major risk factor for ARIA. CAA is highly prevalent in Alzheimer’s disease, and both are driven by
Sin, Mo-Kyung, Luo, Yuan
europepmc +2 more sources
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Manoj Tanwar (17737653) +7 more
core +1 more source
Annals of Neurology, EarlyView.Objective Identification of cerebral amyloid angiopathy (CAA) before its hemorrhagic manifestations remains limited. We aimed to determine whether severe enlarged perivascular spaces in the centrum semiovale (EPVS‐CSO) identify a prehemorrhagic stage of sporadic CAA by predicting the first appearance of CAA‐related hemorrhagic lesions or incident ...
Baris Alten +8 more
wiley +1 more source
Lecanemab over a two-year duration: Key insights from a regional specialty medical center
The Journal of Prevention of Alzheimer's DiseaseBackground and objectives: The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Lisa B.E. Shields +14 more
doaj +1 more source